Dogwood Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $83.7M
- Price
- $2.49
- % Change (Daily % change from the live per-ticker quote feed.)
- +6.87%
- Volume
- 123.6K
About
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Quick stats
Shares outstanding33.6M
Computed float8.6M
Float / shares25.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001818844
Websitehttps://www.dwtx.com
AI Summary
AI-generated1/13
standardbullishclinical trial
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
Dogwood Therapeutics announced it will host a virtual KOL event on September 1, 2026, to discuss positive interim results from its ongoing Phase 2b trial of Halneuron® for chemotherapy-induced neuropathic pain.
The company confirmed that Halneuron® has been tested on over 800 patients to date and that the ongoing Phase 2b study is evaluating 210 to 240 patients across approximately 25 U.S. sites.
Management also highlighted the advancement of the first-ever synthetic formulation of Tetrodotoxin to support Phase 3 development and noted that the lead asset has received Fast Track designation from the FDA.